Vitamin D and Regulation of Histone Methyltransferase EZH2 in Anaplastic Thyroid Carcinoma, From Mechanism to Therapeutic Potential. A Review Article

References

• 1.
  Cocolos A-M, Poiana C. Differentiated Thyroid Cancer Genetic Mechanisms - Focus on Vitamin D Receptor and Methylenetetrahydrofolate Reductase Gene Polymorphisms. Mod Med. 2022;29(1):7–13. https://doi.org/10.31689/rmm.2021.29.1.7.
• 2.
  Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17(1):154. [PubMed ID:30352606]. [PubMed Central ID:PMC6198524]. https://doi.org/10.1186/s12943-018-0903-0.
• 3.
  Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol (Lausanne). 2020;11:102. [PubMed ID:32231639]. [PubMed Central ID:PMC7082927]. https://doi.org/10.3389/fendo.2020.00102.
• 4.
  Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. Philadelphia, Pennsylvania: Elsevier; 2021. p. 549-558.
• 5.
  Norasti F, Yeganeh MZ, Sheikholeslami S, Rad LH, Ghadaksaz HG, Hedayati M. [Plasma levels of omentin in patients with medullary thyroid carcinoma]. Koomesh. 2019;21(1):e15304. Persian.
• 6.
  Sasanakietkul T, Murtha TD, Javid M, Korah R, Carling T. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. Mol Cell Endocrinol. 2018;469:23–37. [PubMed ID:28552796]. https://doi.org/10.1016/j.mce.2017.05.022.
• 7.
  Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2015;100(1):35–42. [PubMed ID:25347569]. [PubMed Central ID:PMC4283016]. https://doi.org/10.1210/jc.2014-2803.
• 8.
  Shakiba E, Movahedi M, Majd A, Hedayati M. [Genetic and epigenetic alteration in thyroid cancer: review article]. Tehran Univ Med J. 2018;75(12):849–59. Persian.
• 9.
  Ivor JB, Griggs RC, Wing EJ, Fitz G. Cecil Essentials of Medicine. Amsterdam, Netherlands: Elsevier; 2016. p. 633-641.
• 10.
  Yang J, Barletta JA. Anaplastic thyroid carcinoma. Semin Diagn Pathol. 2020;37(5):248–56. [PubMed ID:32624319]. https://doi.org/10.1053/j.semdp.2020.06.005.
• 11.
  Bhattacharya S, Mahato RK, Singh S, Bhatti GK, Mastana SS, Bhatti JS. Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches. Life Sci. 2023;332:122110. [PubMed ID:37734434]. https://doi.org/10.1016/j.lfs.2023.122110.
• 12.
  Yuan J, Guo Y. Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management. Cancers (Basel). 2022;15(1). [PubMed ID:36612173]. [PubMed Central ID:PMC9818071]. https://doi.org/10.3390/cancers15010179.
• 13.
  Lyu Z, Zhang Y, Sheng C, Huang Y, Zhang Q, Chen K. Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN. Chin Med J (Engl). 2024;137(21):2567–76. [PubMed ID:39261986]. [PubMed Central ID:PMC11557048]. https://doi.org/10.1097/CM9.0000000000003284.
• 14.
  Pejman Sani M, Mohseni S, Samimi H, Nasiri S, Fallahi B, Mohajeri-Tehrani M, et al. Continued rise in the incidence of thyroid cancer in Iran: true increase or overdiagnosis? J Diabetes Metab Disord. 2025;24(1):68. [PubMed ID:39980844]. [PubMed Central ID:PMC11836260]. https://doi.org/10.1007/s40200-025-01581-0.
• 15.
  Azangou-Khyavy M, Saeedi Moghaddam S, Rezaei N, Esfahani Z, Rezaei N, Azadnajafabad S, et al. National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019. Sci Rep. 2022;12(1):13231. [PubMed ID:35918489]. [PubMed Central ID:PMC9346133]. https://doi.org/10.1038/s41598-022-17115-0.
• 16.
  Lubitz CC, Sadow PM, Daniels GH, Wirth LJ. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid. 2021;31(10):1451–62. [PubMed ID:33860688]. [PubMed Central ID:PMC8591086]. https://doi.org/10.1089/thy.2020.0962.
• 17.
  Li Z, Zhang Y, Wang R, Zou K, Zou L. Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review). Experimental Therapeutic Med. 2019;18(4):2369–77. https://doi.org/10.3892/etm.2019.7869.
• 18.
  Rao SN, Smallridge RC. Anaplastic thyroid cancer: An update. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101678. [PubMed ID:35668021]. https://doi.org/10.1016/j.beem.2022.101678.
• 19.
  Evans LK, Chen H, Taki Labib M, Cronkite DA, Yu AC, Ashendouek M, et al. Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy. Laryngoscope. 2025;135(1):478–84. [PubMed ID:39162326]. [PubMed Central ID:PMC11635144]. https://doi.org/10.1002/lary.31712.
• 20.
  Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities. Biochim Biophys Acta Rev Cancer. 2023;1878(4):188928. [PubMed ID:37257629]. https://doi.org/10.1016/j.bbcan.2023.188928.
• 21.
  Salehian B, Liem SY, Mojazi Amiri H, Maghami E. Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review. Int J Endocrinol Metab. 2019;17(1):e67759. [PubMed ID:30881466]. [PubMed Central ID:PMC6408732]. https://doi.org/10.5812/ijem.67759.
• 22.
  Zhang Y, Chen J, Liu H, Mi R, Huang R, Li X, et al. The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy. Front Immunol. 2022;13:1099892. [PubMed ID:36713412]. [PubMed Central ID:PMC9874864]. https://doi.org/10.3389/fimmu.2022.1099892.
• 23.
  Trager MH, Sah B, Chen Z, Liu L. Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase. Endocrinology. 2021;162(8). [PubMed ID:33928351]. [PubMed Central ID:PMC8237996]. https://doi.org/10.1210/endocr/bqab088.
• 24.
  Liao Q, Yang J, Ge S, Chai P, Fan J, Jia R. Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs. J Pharm Anal. 2023;13(2):127–41. [PubMed ID:36908859]. [PubMed Central ID:PMC9999304]. https://doi.org/10.1016/j.jpha.2022.11.009.
• 25.
  Babic Leko M, Juresko I, Rozic I, Pleic N, Gunjaca I, Zemunik T. Vitamin D and the Thyroid: A Critical Review of the Current Evidence. Int J Mol Sci. 2023;24(4). [PubMed ID:36835005]. [PubMed Central ID:PMC9964959]. https://doi.org/10.3390/ijms24043586.
• 26.
  Masudo K, Suganuma N, Nakayama H, Oshima T, Rino Y, Iwasaki H. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer. In Vivo. 2018;32(1). https://doi.org/10.21873/invivo.11200.
• 27.
  Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104. [PubMed ID:32723346]. [PubMed Central ID:PMC7385862]. https://doi.org/10.1186/s13045-020-00937-8.
• 28.
  Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96(4):1029–38. [PubMed ID:21289264]. https://doi.org/10.1210/jc.2010-1784.
• 29.
  Yamaguchi H, Hung MC. Regulation and Role of EZH2 in Cancer. Cancer Res Treat. 2014;46(3):209–22. [PubMed ID:25038756]. [PubMed Central ID:PMC4132442]. https://doi.org/10.4143/crt.2014.46.3.209.
• 30.
  Xu M, Xu C, Wang R, Tang Q, Zhou Q, Wu W, et al. Treating human cancer by targeting EZH2. Genes Dis. 2025;12(3):101313. [PubMed ID:40028035]. [PubMed Central ID:PMC11870178]. https://doi.org/10.1016/j.gendis.2024.101313.
• 31.
  Volkel P, Dupret B, Le Bourhis X, Angrand PO. Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res. 2015;7(2):175–93. [PubMed ID:25901190]. [PubMed Central ID:PMC4399085].
• 32.
  Sun S, Yu F, Zhang L, Zhou X. EZH2, an on-off valve in signal network of tumor cells. Cell Signal. 2016;28(5):481–7. [PubMed ID:26876615]. https://doi.org/10.1016/j.cellsig.2016.02.004.
• 33.
  Nakayama H, Saito N, Kasajima R, Suganuma N, Rino Y, Masudo K, et al. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines. Anticancer Res. 2023;43(3):1073–7. [PubMed ID:36854530]. https://doi.org/10.21873/anticanres.16252.
• 34.
  de Mello DC, Saito KC, Cristovao MM, Kimura ET, Fuziwara CS. Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer. Int J Mol Sci. 2023;24(9). [PubMed ID:37175580]. [PubMed Central ID:PMC10178714]. https://doi.org/10.3390/ijms24097872.
• 35.
  Lachat C, Boyer-Guittaut M, Peixoto P, Hervouet E. Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2. Epigenomes. 2018;3(1). [PubMed ID:34991274]. [PubMed Central ID:PMC8594212]. https://doi.org/10.3390/epigenomes3010001.
• 36.
  Wen Y, Cai J, Hou Y, Huang Z, Wang Z. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget. 2017;8(23):37974–90. [PubMed ID:28415635]. [PubMed Central ID:PMC5514966]. https://doi.org/10.18632/oncotarget.16467.
• 37.
  Maciejewski A, Lacka K. Vitamin D-Related Genes and Thyroid Cancer-A Systematic Review. Int J Mol Sci. 2022;23(21). [PubMed ID:36362448]. [PubMed Central ID:PMC9658610]. https://doi.org/10.3390/ijms232113661.
• 38.
  Suzuki S, Takenoshita S, Furukawa H, Tsuchiya A. Antineoplastic activity of 1,25(OH)2D3 and its analogue 22-oxacalcitriol against human anaplastic thyroid carcinoma cell lines in vitro. Int J Mol Med. 1999. https://doi.org/10.3892/ijmm.4.6.611.
• 39.
  Henn M, Martin-Gorgojo V, Martin-Moreno JM. Vitamin D in Cancer Prevention: Gaps in Current Knowledge and Room for Hope. Nutrients. 2022;14(21). [PubMed ID:36364774]. [PubMed Central ID:PMC9657468]. https://doi.org/10.3390/nu14214512.
• 40.
  Fetahu IS, Hobaus J, Kallay E. Vitamin D and the epigenome. Front Physiol. 2014;5:164. [PubMed ID:24808866]. [PubMed Central ID:PMC4010791]. https://doi.org/10.3389/fphys.2014.00164.
• 41.
  Peng W, Wang K, Zheng R, Derwahl M. 1,25 dihydroxyvitamin D3 inhibits the proliferation of thyroid cancer stem-like cells via cell cycle arrest. Endocr Res. 2016;41(2):71–80. [PubMed ID:27030645]. https://doi.org/10.3109/07435800.2015.1037048.
• 42.
  Fernandez-Barral A, Bustamante-Madrid P, Ferrer-Mayorga G, Barbachano A, Larriba MJ, Munoz A. Vitamin D Effects on Cell Differentiation and Stemness in Cancer. Cancers (Basel). 2020;12(9). [PubMed ID:32854355]. [PubMed Central ID:PMC7563562]. https://doi.org/10.3390/cancers12092413.
• 43.
  Ng K, Ou FS, Zemla T, McCleary N, Kalyan A, Shusterman M, et al. LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC). Ann Oncol. 2024;35. https://doi.org/10.1016/j.annonc.2024.08.2265.
• 44.
  Omodei MS, Chimicoviaki J, Buttros DAB, Almeida-Filho BS, Carvalho-Pessoa CP, Carvalho-Pessoa E, et al. Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial. Nutr Cancer. 2025;77(6):648–57. [PubMed ID:40098326]. https://doi.org/10.1080/01635581.2025.2480854.
• 45.
  Ozkurt E, Ordu C, Ozmen T, Ilgun AS, Soybir G, Celebi F, et al. Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial. World J Surg. 2025;49(6):1396–405. [PubMed ID:40229998]. [PubMed Central ID:PMC12134193]. https://doi.org/10.1002/wjs.12587.
• 46.
  Trujano-Camacho S, Pulido-Capiz A, Garcia-Gonzalez V, Lopez-Urrutia E, Perez-Plasencia C. Vitamin D as an Epigenetic Regulator: A Hypothetical Mechanism for Cancer Prevention via Inhibition of Oncogenic lncRNA HOTAIR. Int J Mol Sci. 2025;26(16). [PubMed ID:40869316]. [PubMed Central ID:PMC12386503]. https://doi.org/10.3390/ijms26167997.